How to Vet Biologic Suppliers for FDA Compliance

To vet biologic suppliers for FDA compliance, medical practices must verify the manufacturer’s active registration in the FDA Human Cell and Tissue Establishment Registration (HCTERS) database, review donor eligibility and sterility documentation for every lot, and confirm the regulatory classification under 21 CFR Part 1271. Additionally, practice administrators should audit the distributor’s state licensing, cold-chain custody protocols, and marketing materials to ensure they do not make unapproved therapeutic claims that expose the clinic to regulatory liability.

For medical practice managers, sourcing regenerative materials—such as Wharton’s Jelly, amniotic allografts, cord blood, or MSC exosomes—is fundamentally different from purchasing standard medical supplies. When a clinic administers human cells, tissues, and cellular and tissue-based products (HCT/Ps), the regulatory burden does not stop at the manufacturer's loading dock. Your practice’s liability, accreditation, and clinical reputation depend on the compliance posture of your supply chain.

Understanding the Regulatory Baseline: Section 361 vs. Section 351

Before requesting vendor documentation, procurement leaders need a clear operational understanding of how the FDA regulates human tissue products under 21 CFR Part 1271. The framework divides products into two primary pathways based on how they are processed and intended to be used.

Section 361 HCT/Ps

Products regulated solely under Section 361 of the Public Health Service (PHS) Act are not required to undergo premarket approval, provided they meet four strict criteria simultaneously:

• They are minimally manipulated (processing does not alter the original relevant characteristics of the tissue).
• They are intended for homologous use only (performing the same basic function in the recipient as in the donor), as reflected by the labeling, advertising, and objective intent of the manufacturer.
• Their manufacture does not involve the combination of the cells or tissues with another article, with limited exceptions for preserving and storage agents.
• They either do not have a systemic effect and are not dependent upon the metabolic activity of living cells for their primary function, or, if they do, they are for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.

Section 351 Biologics

If an allograft or cellular product fails to meet even one of the Section 361 criteria, it is regulated as a drug, device, or biological product under Section 351 of the PHS Act and the Federal Food, Drug, and Cosmetic Act. To be lawfully marketed for clinical treatment, a Section 351 product requires an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application for clinical trials.

When evaluating how to vet biologic suppliers for FDA compliance, the central operational risk is purchasing a product marketed as a Section 361 tissue that the FDA actually considers an unapproved Section 351 drug due to more-than-minimal manipulation or non-homologous promotional claims.

The Procurement Compliance Checklist

Practice administrators should require prospective suppliers to complete a standardized compliance packet before onboarding any regenerative product line. Use the following checklist to evaluate both the tissue processor (manufacturer) and the distributor.

• Active FDA Establishment Registration: Verify the tissue bank directly in the public FDA HCTERS database using their FDA Establishment Identifier (FEI) number. Ensure the status is "Active" and check the specific types of tissues and activities (e.g., recovery, processing, packaging, distribution) listed on their registration. Note that registration is a self-reporting requirement and does not constitute ”FDA approval.”
• Inspection and Enforcement History: Search the FDA Data Dashboard and Warning Letters database for the manufacturer and distributor names. Look for Form FDA 483 inspectional observations, Untitled Letters, or Warning Letters citing Current Good Tissue Practice (CGTP) deviations or unapproved drug claims.
• State Distributor Licensing: Confirm that the vendor holds appropriate state-level medical device or tissue distribution licenses where required. For example, Dallas Regenerative Solutions operates as a licensed Texas medical device distributor (License #1002308), providing a verifiable chain of custody between vetted laboratories and clinical practices.
• Accreditation Credentials: Check whether the processing laboratory holds voluntary accreditation from recognized bodies such as the American Association of Tissue Banks (AATB) or maintains ISO-certified cleanroom facilities.
• Donor Eligibility and Communicable Disease Testing: Require a sample Certificate of Analysis (CoA) and donor summary record. Under 21 CFR 1271 Subpart C, records must verify that the donor was screened and tested negative for relevant communicable disease agents (including HIV, Hepatitis B and C, syphilis, and WNV) using FDA-licensed, approved, or cleared donor screening tests.
• Lot-Specific Sterility and Endotoxin Testing: Confirm whether the processor performs USP <71> sterility testing (a standard 14-day culture protocol) and USP <85> bacterial endotoxin testing prior to releasing a lot for distribution, rather than releasing products ”at risk” before final culture reads are complete.
• Cold-Chain Validation and Receiving SOPs: Audit the shipping methodology. Cryopreserved biologics require validated dry ice or liquid nitrogen dry-shipper containers capable of maintaining temperature integrity beyond the expected transit window. Request the supplier's policy on temperature excursions during transit.
• Adverse Event and Tissue Tracking Protocols: Verify that the vendor maintains a bidirectional tracking system that allows a specific vial's unique identification code to be traced from the donor to the recipient, and ask for a copy of their adverse reaction reporting SOP.

Evaluating Marketing Claims and ”Red Flags”

The FDA determines a product's ”objective intent” not just by its package insert, but by the promotional statements made by sales representatives, websites, and brochures. Even if a tissue is minimally manipulated in the lab, a supplier can cross the line into unapproved drug territory through improper marketing.

Administrators should immediately flag vendors who engage in the following practices:

• Claiming ”FDA Approval” for 361 Tissues: Section 361 HCT/Ps are registered, not approved. Any vendor claiming their umbilical cord or amniotic tissue is ”FDA-approved” is misrepresenting the regulatory framework.
• Making Specific Disease-Treatment Claims: Sales sheets or white papers claiming that a non-BLA tissue product cures, treats, or mitigates systemic diseases (such as diabetes, Alzheimer's, neuropathy, or systemic autoimmune conditions) violate homologous use boundaries and create severe compliance exposure for the purchasing clinic.
• Refusing to Name the Processing Lab: Private-label distributors who refuse to disclose the underlying FDA-registered tissue establishment on the product labeling or CoA prevent your practice from fulfilling its mandatory tissue tracking obligations.
• Providing Coaching on Improper Insurance Billing: Be cautious of suppliers who build their sales pitch around aggressive, guaranteed reimbursement strategies using unmatched Q-codes or CPT codes without clear payer policy coverage.

Clinical Alignment: What Physicians Need from the Vetting Process

While practice managers focus on documentation, cold-chain logistics, and liability mitigation, the treating physicians within your group have distinct clinical requirements that must be integrated into the vendor evaluation. Whether your clinicians operate in orthopedics, pain management, or aesthetics, product consistency directly impacts clinical workflow.

Physicians rely on procurement to ask technical processing questions that affect how the material handles at the point of care:

• Preservation Media and Cryoprotectants: Clinicians need to know the exact concentration of cryoprotectants like dimethyl sulfoxide (DMSO) or whether the product is DMSO-free, as this influences patient comfort and handling protocols.
• Processing Methodology: For structural allografts like Wharton’s Jelly or amniotic membrane preparations, physicians need clarity on how the extracellular matrix is preserved during processing and whether harsh irradiation or chemical sterilization was used.
• Point-of-Care Alternatives: In many cases, practices choose to balance their inventory of allogeneic tissues with autologous point-of-care systems—such as high-yield Platelet-Rich Plasma (PRP) kits or regenerative devices like focused shockwave and high-power laser therapy—to give clinicians flexible, compliant modalities tailored to each patient's clinical presentation.

Building an Internal Tissue Compliance Workflow

Vetting the supplier is only the first half of compliance; the second half happens inside your clinic. Once a compliant supplier is selected, the practice manager should establish a standard operating procedure (SOP) for biologic inventory management:

1. Centralized Vendor File: Maintain digital and physical binders containing the supplier's current FDA establishment registration, state licenses, AATB certificates, and W-9, updated annually.
2. Receiving Inspection Log: Train clinical staff to inspect every shipment upon arrival, verify that dry ice has not fully sublimated, check vial integrity, and log the lot number, expiration date, and unique tissue ID into your inventory system.
3. Patient Chart Traceability: Ensure the electronic health record (EHR) captures the exact lot number and tissue identification number in the patient's procedure note, alongside the duplicate peel-off tracking labels provided with the allograft.

What This Means for Your Practice

Establishing a rigorous vetting protocol protects your medical licenses, prevents costly inventory seizures or regulatory inquiries, and ensures your clinicians are working with thoroughly screened, properly handled materials.

Concrete next actions for practice administrators:

• Audit Current Inventory: Pull the package inserts and Certificates of Analysis for every biologic currently in your clinic's freezer or refrigerator and verify each manufacturer in the FDA HCTERS database.
• Review Clinic Marketing: Ensure your practice's website, patient intake forms, and informed consent documents accurately describe your regenerative offerings without echoing unapproved disease-treatment claims.
• Standardize Vendor Onboarding: Implement the compliance checklist above as a mandatory gate before any physician or staff member can bring a new biologic vendor into the practice.

If your practice is auditing its current regenerative supply chain or expanding its service lines, we invite you to contact Dallas Regenerative Solutions to review our laboratory documentation, licensing credentials, and compliant product portfolio.